Presentation is loading. Please wait.

Presentation is loading. Please wait.

The decision tree with the two alternatives.

Published byChad Pierce Modified over 5 years ago

Similar presentations

Presentation on theme: "The decision tree with the two alternatives."— Presentation transcript:

1 The decision tree with the two alternatives.
The decision tree with the two alternatives. Alternative 1: women diagnosed with breast cancer offered testing for BRCA mutation and family members of carriers tested. Alternative 2: women diagnosed with BC evaluated based on family history and candidates referred to testing and family members followed up. Probabilities (P1–P15) added. BC, breast cancer; mut, mutation; pts, patients; undiagn, undiagnosed. Jan Norum et al. ESMO Open 2018;3:e000328 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "The decision tree with the two alternatives."

Similar presentations

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
(A) Safety profile overview.

(A) Safety profile overview.
Detection rate for EGFR mutations in cfDNA.

Detection rate for EGFR mutations in cfDNA.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
(A) Number of KRAS mutations detected by mutation concentration by each technology with 100 copies mutant allele frequency. (A) Number of KRAS mutations.

(A) Number of KRAS mutations detected by mutation concentration by each technology with 100 copies mutant allele frequency. (A) Number of KRAS mutations.
Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).

Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).
Kaplan-Meier curves for overall survival (OS) probability.

Kaplan-Meier curves for overall survival (OS) probability.

Similar presentations

Ads by Google